JACoW logo

Joint Accelerator Conferences Website

The Joint Accelerator Conferences Website (JACoW) is an international collaboration that publishes the proceedings of accelerator conferences held around the world.


RIS citation export for SUSPFO110: Beam Characterisation Using MEDIPIX3 and EBT3 Film at the Clatterbridge Proton Therapy Beamline

TY  - CONF
AU  - Yap, J.S.L.
AU  - Bal, N.J.S.
AU  - Fransen, M.
AU  - Kacperek, A.
AU  - Linde, F.
AU  - Parsons, J.L.
AU  - Resta-López, J.
AU  - Schnuerer, R.
AU  - Welsch, C.P.
ED  - Boland, Mark
ED  - Tanaka, Hitoshi
ED  - Button, David
ED  - Dowd, Rohan
ED  - Schaa, Volker RW
ED  - Tan, Eugene
TI  - Beam Characterisation Using MEDIPIX3 and EBT3 Film at the Clatterbridge Proton Therapy Beamline
J2  - Proc. of IPAC2019, Melbourne, Australia, 19-24 May 2019
CY  - Melbourne, Australia
T2  - International Particle Accelerator Conference
T3  - 10
LA  - english
AB  - The Clatterbridge Cancer Centre (CCC) in the UK is a particle therapy facility providing treatment for ocular cancers using a 60 MeV passively scattered proton therapy beam. A model of the beamline using the Monte Carlo Simulation toolkit Geant4 has been developed for accurate characterisation of the beam. In order to validate the simulation, a study of the beam profiles along the delivery system is necessary. Beam profile measurements have been performed at multiple positions in the CCC beam line using both EBT3 GAFchromic film and Medipix3, a single quantum counting chip developed specifically for medical applications, typically used for x-ray detection. This is the first time its performance has been tested within a clinical, high proton flux environment. EBT3 is the current standard for conventional radiotherapy film dosimetry and was used to determine the dose and for correlation to fluence measured by Medipix3. The count rate linearity and doses recorded with Medipix3 were evaluated across the full range of available beam intensities, up to 3.12 x 10¹⁰ protons/s. The applicability of Medipix3 for proton therapy dosimetry is discussed and compared against the performance of EBT3.
PB  - JACoW Publishing
CP  - Geneva, Switzerland
SP  - 3510
EP  - 3513
DA  - 2019/06
PY  - 2019
SN  - 978-3-95450-208-0
DO  - DOI: 10.18429/JACoW-IPAC2019-THPMP033
UR  - http://jacow.org/ipac2019/papers/thpmp033.pdf
ER  -